BAYRY
Bayer AG (ADR)

2,759
Mkt Cap
$26.48B
Volume
360,333.00
52W High
$8.70
52W Low
$4.79
PE Ratio
-7.99
BAYRY Fundamentals
Price
$7.75
Prev Close
$7.70
Open
$7.69
50D MA
$8.09
Beta
0.48
Avg. Volume
380,260.90
EPS (Annual)
-$0.7025
P/B
0.85
Rev/Employee
$543,158.75
Loading...
Loading...
News
all
press releases
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Here is how Medpace (MEDP) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Zacks·5d ago
News Placeholder
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Zacks·5d ago
News Placeholder
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Zacks·9d ago
News Placeholder
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Zacks·17d ago
News Placeholder
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Zacks·19d ago
News Placeholder
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·20d ago
News Placeholder
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
Zacks·24d ago
News Placeholder
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Zacks·25d ago

Latest BAYRY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.